216 related articles for article (PubMed ID: 24336126)
1. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.
Maroz A; Stachorski L; Emmrich S; Reinhardt K; Xu J; Shao Z; Käbler S; Dertmann T; Hitzler J; Roberts I; Vyas P; Juban G; Hennig C; Hansen G; Li Z; Orkin S; Reinhardt D; Klusmann JH
Leukemia; 2014 Jun; 28(6):1259-70. PubMed ID: 24336126
[TBL] [Abstract][Full Text] [Related]
2. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
3. Blasts in transient leukaemia in neonates with Down syndrome differentiate into basophil/mast-cell and megakaryocyte lineages in vitro in association with down-regulation of truncated form of GATA1.
Miyauchi J; Ito Y; Tsukamoto K; Takahashi H; Ishikura K; Sugita K; Miyashita T
Br J Haematol; 2010 Mar; 148(6):898-909. PubMed ID: 20064153
[TBL] [Abstract][Full Text] [Related]
4. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
5. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
6. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
7. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
8. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
9. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Juban G; Sakakini N; Chagraoui H; Cruz Hernandez D; Cheng Q; Soady K; Stoilova B; Garnett C; Waithe D; Otto G; Doondeea J; Usukhbayar B; Karkoulia E; Alexiou M; Strouboulis J; Morrissey E; Roberts I; Porcher C; Vyas P
Haematologica; 2021 Apr; 106(4):1106-1119. PubMed ID: 32527952
[TBL] [Abstract][Full Text] [Related]
11. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
12. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
Hasle H; Kline RM; Kjeldsen E; Nik-Abdul-Rashid NF; Bhojwani D; Verboon JM; DiTroia SP; Chao KR; Raaschou-Jensen K; Palle J; Zwaan CM; Nyvold CG; Sankaran VG; Cantor AB
Blood; 2022 May; 139(21):3159-3165. PubMed ID: 34758059
[TBL] [Abstract][Full Text] [Related]
13. GATA1 mutations in acute leukemia in children with Down syndrome.
Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
[TBL] [Abstract][Full Text] [Related]
14. The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.
Halsey C; Docherty M; McNeill M; Gilchrist D; Le Brocq M; Gibson B; Graham G
J Hematol Oncol; 2012 Aug; 5():45. PubMed ID: 22853316
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.
Shaham L; Vendramini E; Ge Y; Goren Y; Birger Y; Tijssen MR; McNulty M; Geron I; Schwartzman O; Goldberg L; Chou ST; Pitman H; Weiss MJ; Michaeli S; Sredni B; Göttgens B; Crispino JD; Taub JW; Izraeli S
Blood; 2015 Feb; 125(8):1292-301. PubMed ID: 25533034
[TBL] [Abstract][Full Text] [Related]
16. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
17. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
Stankiewicz MJ; Crispino JD
Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
[TBL] [Abstract][Full Text] [Related]
18. The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice.
Ishihara D; Hasegawa A; Hirano I; Engel JD; Yamamoto M; Shimizu R
Exp Hematol Oncol; 2024 Feb; 13(1):24. PubMed ID: 38409186
[TBL] [Abstract][Full Text] [Related]
19. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
[TBL] [Abstract][Full Text] [Related]
20. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
